Moreover, because TLR4/NF-κB appears to play a predominant role in inflammation and matrix degradation in atherosclerosis, these observations may provide a foundation for the development of innovative therapeutic strategies, such as antagonists of TLR4 or TLR4 siRNAs, for the prevention and therapy of atherosclerosis and its complications. This evidence concerns the gene NFKB1 and atherosclerosis.